Small Business: Cell and Molecular Biology – BCTA (15)
This special emphasis panel reviews small business applications in the general area of cell biology, molecular biology, and genetics. Emphasis is on technology developments in cellular cultures, assays, measurements, and imaging, or technology developments in genetic assays, diagnostics, sequencing, and engineering.
Review Dates
A roster for the panel will be posted here, at least 30 days prior to the review meeting
Review Dates
Topics
- Novel cell-based technologies for monitoring molecular interactions and/or cellular activity and high-throughput/high-content assay design
- Development of new technologies for cell culture, separations, and sorting, including flow cytometry and stem cells
- Development of new technologies for transgenic systems
- Development of new technologies and assays for genetics, genomics, and functional genomics
- Cryopreservation/vitrification of cells
Shared Interests and Overlaps
There are shared interests with Drug Discovery (DDTD (10)). Applications using cells for drug discovery or pharmacological screenings may be assigned to DDTD (10). Applications developing new cell-based technologies and assays may be assigned to BCTA (15).
There are shared interests with Biomaterials, Delivery, and Nanotechnology (BCTB (10)). Applications integrating cells into biomaterial constructs and/or studying the integration of biomaterials into cellular environments may be assigned to BCTB (10). Applications developing new cell-based technologies and assays may be assigned to BCTA (15). Tissue engineering and microphysiological systems (e.g. organ-on-a-chip) applications are the domain of BCTB (10).
There are shared interests with Bioanalytical Chemistry, Chemistry, Biophysics, and Assay Development (BCTA (10)). Applications developing assays or technologies that are not cell-based may be assigned to BCTA (10). Applications developing assays with a cell component may be assigned to BCTA (15).
There are shared interests with Instrumentation, Environmental, and Occupational Safety (BCTC (12)). Applications developing technologies with a significant engineering component may be assigned to BCTC (12), whereas applications having a dominant cell biology component may be assigned to BCTA (15).
In the area of cryopreservation, there are shared interests with organ- or clinically based small business panels. Applications developing cryopreservation strategies for organs and large tissues may be assigned to the relevant organ or clinically based small business panel, whereas applications developing cryopreservation of cells may be assigned to BCTA (15).
There are shared interests between the small business panels in the Bioengineering, Computation, and Technology Development review branches (BCTA (10), BCTB (10) BCTC (12), BCTB (14), and BCTA (15)) and Small Business: Clinical Care and Health Interventions (CCTD (10)) in the development of devices and technologies. Applications are reviewed in the BCT branches if they are related to disease-agnostic diagnostic technologies (BCTB (10)) classification systems (BCTB (14)), sensors and imaging devices (BCTC (12)) and genomics technologies (BCTA (15)). Applications are reviewed in CCTD (10) if they involve the use of biomedical engineering to influence health risks and behaviors.
